Study of study drug with bevacizumab for maintenance in ovarian cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This study tests whether adding a new pill (INCB123667) to the usual maintenance drug bevacizumab (Avastin) can keep ovarian cancer from coming back, compared to bevacizumab alone. It is for women who have finished their first chemo and are in remission or have stable disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your cancer is stage III or IV and is a common type (high-grade serous, high-grade endometrioid, or clear cell) of ovarian, fallopian tube, or primary peritoneal cancer.
- You have had surgery to remove as much of the tumor as possible, either before or after your first chemotherapy.
- You have completed at least 6 cycles (but no more than 8) of standard first-line chemo (platinum and taxane) combined with bevacizumab (Avastin).
- After chemo, your cancer is either not growing or has shrunk (no new tumors or recurrence).
- A lab test shows that your tumor makes high levels of a protein called cyclin E1.
- You do not have a harmful BRCA gene change in your tumor and are not eligible for a PARP inhibitor (a different type of maintenance drug).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new experimental drug (JPI-547) combined with bevacizumab (a targeted therapy) as maintenance treatment for recurrent ovarian cancer after initial response to platinum-based chemo. The goal is to see if this combination can keep the cancer from growing longer than standard care.
This trial tests whether a combination of medications (hydroxychloroquine, everolimus, and others) can help keep ovarian cancer from coming back after successful platinum chemotherapy plus Avastin. It is for people whose cancer responded well to their most recent chemo and who can continue Avastin maintenance.
This study tests whether adding a targeted therapy (trastuzumab) to the usual maintenance drug (bevacizumab) helps keep ovarian cancer from coming back after first-line chemo. It is for people with certain genetic markers and who have completed initial treatment without the cancer growing.
This trial compares a new drug called Rina-S with standard care to see if it helps keep ovarian cancer from coming back. It is for people who have finished their first round of platinum-based chemotherapy and are in remission or stable.
This study tests a new maintenance therapy for people with advanced ovarian, fallopian tube, or primary peritoneal cancer who have finished their first round of chemo and are showing good response. The goal is to see if this treatment helps delay the cancer from coming back.
This trial compares two drug combinations (fluzoparib plus bevacizumab versus olaparib plus bevacizumab) given after initial chemotherapy to keep advanced ovarian cancer from coming back. Participants must have a specific genetic marker (HRD-positive) and have responded well to their first treatment.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.